HOUSE OF REPRESENTATIVES |
H.B. NO. |
70 |
THIRTY-SECOND LEGISLATURE, 2023 |
H.D. 1 |
|
STATE OF HAWAII |
|
|
|
|
|
|
||
|
A BILL FOR AN ACT
RELATING TO CONTROLLED SUBSTANCES.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
SECTION 1. Section 328G-3, Hawaii Revised Statutes, is amended by amending subsection (f) to read as follows:
"(f) No person shall sell[,] or
hold, offer, or distribute for sale any hemp product [into]:
(1) Into which a synthetic cannabinoid has
been added[.]; or
(2) That contains cannabinoids created through
isomerization, including Delta 6 cis or trans tetrahydrocannabinol, and their
optical isomers (other names: Delta 8 cis or trans tetrahydrocannabinol, and
their optical isomers); provided that this paragraph shall not be construed to
prohibit a medical cannabis dispensary licensed pursuant to chapter 329D from selling
or holding, offering, or distributing for sale cannabis or manufactured cannabis
products that contain naturally-occurring Delta 8 tetrahydrocannabinol."
SECTION 2. Section 329-14, Hawaii Revised Statutes, is amended by amending subsection (g) to read as follows:
"(g) Any of the following cannabinoids, their
salts, isomers, and salts of isomers, unless specifically excepted, whenever
the existence of these salts, isomers, and salts of isomers is possible within
the specific chemical designation:
(1) Tetrahydrocannabinols;
meaning tetrahydrocannabinols naturally contained in a plant of the genus
Cannabis (cannabis plant), as well as synthetic equivalents of the substances
contained in the plant, or in the resinous extractives of Cannabis, sp. or
synthetic substances, derivatives, and their isomers with similar chemical
structure and pharmacological activity to those substances contained in the
plant, such as the following: Delta 1 cis or trans tetrahydrocannabinol, and
their optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their
optical isomers[;] (other names: Delta 8 cis or trans
tetrahydrocannabinol, and their optical isomers); and Delta 3,4 cis
or trans-tetrahydrocannabinol, and its optical isomers (since nomenclature of
these substances is not internationally standardized, compounds of these
structures, regardless of numerical designation of atomic positions, are
covered);
(2) Naphthoylindoles; meaning any compound
containing a 3‑(1-naphthoyl)indole structure with substitution at the
nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
group, whether or not further substituted in the indole ring to any extent and
whether or not substituted in the naphthyl ring to any extent;
(3) Naphthylmethylindoles; meaning any compound
containing a 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at
the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
2-(4-morpholinyl) ethyl group whether or not further substituted in the indole
ring to any extent and whether or not substituted in the naphthyl ring to any
extent;
(4) Naphthoylpyrroles; meaning any compound
containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen
atom of the pyrrole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) ethyl
group whether or not further substituted in the pyrrole ring to any extent,
whether or not substituted in the naphthyl ring to any extent;
(5) Naphthylmethylindenes; meaning any compound
containing a naphthylideneindene structure with substitution at the 3-position
of the indene ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl
group whether or not further substituted in the indene ring to any extent,
whether or not substituted in the naphthyl ring to any extent;
(6) Phenylacetylindoles; meaning any compound
containing a 3-phenylacetylindole structure with substitution at the nitrogen
atom of the indole ring by a alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
2-(4-morpholinyl) ethyl group whether or not further substituted in the indole
ring to any extent, whether or not substituted in the phenyl ring to any
extent;
(7) Cyclohexylphenols;
meaning any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with
substitution at the 5-position of the phenolic ring by a alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl
or 2-(4-morpholinyl) ethyl group whether or not substituted in the cyclohexyl
ring to any extent;
(8) Benzoylindoles; meaning any compound
containing a 3‑(benzoyl) indole structure with
substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl,
or 2-(4-morpholinyl) ethyl group whether or not further substituted in the
indole ring to any extent and whether or not substituted in the phenyl ring to
any extent;
(9) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-naphthalenylmethanone (another trade
name is WIN 55,212-2);
(10) (6a,10a)-9-(hydroxymethyl)-6,
6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
(Other trade names are: HU-210/HU-211);
(11) Tetramethylcyclopropanoylindoles; meaning any
compound containing a 3-tetramethylcyclopropanoylindole structure with
substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
tetrahydropyranylmethyl group, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the tetramethylcyclopropyl
ring to any extent;
(12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: APINACA, AKB48);
(13) Quinolin-8-yl
1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric
isomers, salts, and salts of isomers (Other names: PB-22; QUPIC);
(14) Quinolin-8-yl
1-(5fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and
geometric isomers, salts, and salts of isomers (Other names: 5‑fluoro-PB-22;
5F-PB-22);
(15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: AB-FUBINACA);
(16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: ADB-PINACA);
(17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: AB-CHMINACA);
(18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide,
and geometric isomers, salts, and salts of isomers (Other names: AB-PINACA);
(19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone,
and geometric isomers, salts, and salts of isomers (Other names: THJ-2201);
(20) Methyl
(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate, and geometric isomers,
salts, and salts of isomers (Other names: FUB-AMB, Methyl
2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate,
MMB-FUBINACA, AMB-FUBINACA);
(21) (S)-methyl
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, and
geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-AMB,
5-fluoro-AMP);
(22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide,
and geometric isomers, salts, and salts of isomers (Other names: AKB48 N-(5‑fluoropentyl)
analog, 5F-AKB48, APINACA 5-fluoropentyl analog, 5F-APINACA);
(23) N-adamantyl-1-fluoropentylindole-3-Carboxamide,
and geometric isomers, salts, and salts of isomers (Other names: STS-135,
5F-APICA; 5-fluoro-APICA);
(24) Naphthalen-1-yl
1-(5-fluoropentyl)-1H-indole-3-carboxylate, and geometric isomers, salts, and
salts of isomers (Other names: NM2201; CBL2201);
(25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide,
and geometric isomers, salts, and salts of isomers (Other names: MAB-CHMINACA
and ADB-CHMINACA);
(26) Methyl
2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (Other
names: 5F‑ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
positional, and geometric isomers, salts, and salts of isomers;
(27) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, its optical, positional,
and geometric isomers, salts, and salts of isomers (Other names: SGT-78; 4-CN-CUMYL
BINACA; 4-CN-CUMYL-BUTINACA; CUMYL‑CB-PINACA;
CUMYL-CYBINACA; 4-cyano-CUMYL-BUTINACA; CUMYL-4CN-BINACA);
(28) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (Other name: 5F-AB-PINACA);
(29) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (Other names: MMB‑CHMICA; AMB-CHMICA);
(30) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Other names: 5F‑CUMYL-P7AICA); and
(31) Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA)."
SECTION 3. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
SECTION 4. This Act shall take effect on June 30, 3000.
Report Title:
Hemp Products; Uniform Controlled Substances Act; Schedule I; Cannabinoids; Delta 8 Tetrahydrocannabinol
Description:
Prohibits the sale and distribution of hemp products that contain cannabinoids created through isomerization, including Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers (other names: Delta 8 cis or trans tetrahydrocannabinol, and their optical isomers). Exempts certain cannabis and manufactured cannabis product sales from the prohibition. Inserts alternative names for Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers into the list of schedule I controlled substances. Effective 6/30/3000. (HB70 HD1)
The summary description
of legislation appearing on this page is for informational purposes only and is
not legislation or evidence of legislative intent.